# BioCina

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/biocina
Canonical HTML page: https://gethealthbrief.com/entity/biocina

## Timeline

- **2027**: Clinical Evaluation — Anticipated delivery of therapeutic batches for Phase I/II clinical trials.
- **2026-Q4**: cGMP Manufacturing — Commencement of current Good Manufacturing Practice (cGMP) runs for clinical supply.
- **2026-Q3**: Process Development — Expected completion of initial process optimization and scale-up activities.
- **2026-03-17**: Program Initiation — BioCina officially starts the comprehensive manufacturing program for the Patry therapeutic.

## Recent coverage (1 stories)

### BioCina Scales Manufacturing for Patry's Novel Delirium Therapeutic
2026-03-17 03:32:32 · Sentiment: Positive · Impact: 6/10 · Sources: 2

BioCina has launched a comprehensive manufacturing program for the Patry proprietary injectable therapeutic, a novel treatment designed to alleviate delirium. This partnership marks a critical milestone in bringing a specialized solution to a high-need clinical area with limited current treatment options.
Full story: https://gethealthbrief.com/story/biocina-manufacturing-patry-delirium-therapeutic

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.